Recent Performance Snapshot for STERIS Stock

STERIS (STE) has drawn investor attention after a period where short term and longer term returns have moved in different directions, with the stock showing mixed performance across the past week, month and past 3 months.

At a share price of $215.67, STERIS has recently shown stronger short term momentum, with a 1 day share price return of 2.41% and 7 day share price return of 6.45%, while the year to date share price return is down 13.75% and the 1 year total shareholder return is down 8.72%. This suggests recent optimism is emerging after a weaker period for holders.

If STERIS has you reassessing where growth and resilience might come from next, it could be worth scanning for other healthcare technology opportunities through the 39 healthcare AI stocks

With STERIS shares sitting at $215.67 and recent returns pulling in different directions, the key question is whether the current valuation still leaves a margin of safety or if the market is already pricing in future growth.

Most Popular Narrative: 16% Undervalued

Compared with STERIS's last close at $215.67, the most followed narrative places fair value at about $256.86, framing the current price as a discount that relies heavily on future earnings strength and recurring revenue.

Continued expansion of STERIS's consumables and services segments with high recurring revenue and margin visibility positions the company to benefit from increasing healthcare expenditures and adoption of best-practice infection control standards, supporting both revenue and margin expansion.

Read the complete narrative. Read the complete narrative.

Curious what kind of revenue mix and profit margin profile could justify a higher fair value than today's price, while also assuming a richer future earnings multiple? The key assumptions blend steady top line growth, rising profitability and a projected valuation level above the broader medical equipment group, all filtered through a specific discount rate and share count path that shape the end result.

Result: Fair Value of $256.86 (UNDERVALUED)

However, STERIS still faces tariff exposure on key inputs and ongoing healthcare reimbursement and payment pressures, which could weigh on margins and temper the current upside narrative.

Another View on STERIS Valuation

While the analyst narrative points to STERIS as about 16% undervalued at a fair value of $256.86, the current P/E of 26.9x is higher than both the peer average of 21.9x and the US Medical Equipment industry at 25.7x, and above a fair ratio of 22.8x. This raises the question of how much optimism is already in the price.

For a closer look at what this gap between the current P/E, peers, and the fair ratio might mean for valuation risk, see what the numbers say in our valuation breakdown through the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals on value and expectations circling STERIS, the real edge comes from checking the details yourself and deciding what truly matters for your portfolio. To weigh both the concerns and the potential upside in one place, take a closer look at the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond STERIS?

If STERIS has sharpened your focus on quality, do not stop here. Broaden your watchlist now so you are not late to the next opportunity.

• Zero in on potential bargains by scanning companies that combine quality fundamentals with attractive pricing through the 44 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies that offer yield and resilience using the 8 dividend fortresses.
• Prioritise capital preservation by checking companies that score well on stability and financial risk through the 71 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.